0001127602-24-006213.txt : 20240221
0001127602-24-006213.hdr.sgml : 20240221
20240221212830
ACCESSION NUMBER: 0001127602-24-006213
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240216
FILED AS OF DATE: 20240221
DATE AS OF CHANGE: 20240221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Murphy Nicole
CENTRAL INDEX KEY: 0001910644
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19311
FILM NUMBER: 24662043
MAIL ADDRESS:
STREET 1: BIOGEN INC.
STREET 2: 225 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOGEN INC.
CENTRAL INDEX KEY: 0000875045
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330112644
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 225 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 7814642000
MAIL ADDRESS:
STREET 1: 225 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: BIOGEN IDEC INC.
DATE OF NAME CHANGE: 20070427
FORMER COMPANY:
FORMER CONFORMED NAME: BIOGEN IDEC INC
DATE OF NAME CHANGE: 20031112
FORMER COMPANY:
FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE
DATE OF NAME CHANGE: 19970530
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-02-16
0000875045
BIOGEN INC.
BIIB
0001910644
Murphy Nicole
225 BINNEY STREET
CAMBRIDGE
MA
02142
1
Head of Pharm Ops and Tech
0
Common Stock
2024-02-16
4
M
0
856
0
A
9623.9895
D
Common Stock
2024-02-16
4
F
0
414
219.08
D
9209.9895
D
Common Stock
2024-02-16
4
M
0
404
0
A
9613.9895
D
Common Stock
2024-02-16
4
F
0
196
219.08
D
9417.9895
D
Performance Stock Unit
0
2024-02-16
4
M
0
856
0
D
2024-02-18
2024-02-18
Common Stock
856
0
D
Restricted Stock Unit
0
2024-02-16
4
M
0
404
0
D
2024-02-18
Common Stock
404
504
D
Restricted Stock Unit
0
2024-02-16
4
J
0
504
0
D
2024-02-18
Common Stock
504
0
D
This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
/s/ Wendell Taylor, attorney in fact for Nicole Murphy
2024-02-21